|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:dateCreated |
2011-2-10
|
|
pubmed:abstractText |
Hepatocellular carcinoma (HCC) is the fifth most common neoplasia in the world. In the past, treatment of advanced HCC with conventional antineoplastic drugs did not result in satisfactory outcomes: recently, in this patient population the oral multikinase inhibitor sorafenib has been able to induce a statistically significant improvement of overall survival. Similarly to other anti-angiogenic drugs employed in other tumour types, also sorafenib seldom induces the dimensional tumour shrinking usually observed with conventional cytotoxic drugs: data gathered from studies carried out with sorafenib and other competitors under development do not report any complete response in HCV-induced HCC.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/21241463-10518310,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21241463-11343235,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21241463-11592607,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21241463-11668491,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21241463-15196530,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21241463-16715676,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21241463-17167981,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21241463-18477802,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21241463-18650514,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21241463-18840822,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21241463-18928548,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21241463-19574982,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21241463-20099300,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21241463-20440771,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21241463-20559534,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21241463-20578262,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21241463-8594428
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1471-230X
|
|
pubmed:author |
pubmed-author:AltomareEmanueleE,
pubmed-author:BargelliniIreneI,
pubmed-author:BartolozziCarloC,
pubmed-author:BattagliaValentinaV,
pubmed-author:BertiniMarcoM,
pubmed-author:BertoniMicheleM,
pubmed-author:BozziElenaE,
pubmed-author:BresciGiampaoloG,
pubmed-author:CapriaAlfonsoA,
pubmed-author:GiannelliGianluigiG,
pubmed-author:RomanoAntonioA,
pubmed-author:SaccoRodolfoR
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
11
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4
|
|
pubmed:dateRevised |
2011-7-25
|
|
pubmed:meshHeading |
pubmed-meshheading:21241463-Aged, 80 and over,
pubmed-meshheading:21241463-Antineoplastic Agents,
pubmed-meshheading:21241463-Benzenesulfonates,
pubmed-meshheading:21241463-Carcinoma, Hepatocellular,
pubmed-meshheading:21241463-Hepatitis C, Chronic,
pubmed-meshheading:21241463-Humans,
pubmed-meshheading:21241463-Liver Cirrhosis,
pubmed-meshheading:21241463-Liver Neoplasms,
pubmed-meshheading:21241463-Male,
pubmed-meshheading:21241463-Pyridines,
pubmed-meshheading:21241463-Remission Induction,
pubmed-meshheading:21241463-Treatment Outcome,
pubmed-meshheading:21241463-alpha-Fetoproteins
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Complete response for advanced liver cancer during sorafenib therapy: case report.
|
|
pubmed:affiliation |
Gastroenterology Department, Pisa University Hospital, Via Paradisa 2, 56124 Pisa, Italy. saccorodolfo@hotmail.com
|
|
pubmed:publicationType |
Journal Article,
Case Reports
|
